Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy
Menée sur 6 842 patients atteints d'un cancer localisé de la prostate traité par prostatectomie radicale entre 2000 et 2011, cette étude rétrospective évalue l'effet de l'utilisation de statines sur le risque de récidive biochimique
Background : The impact of statin use on biochemical recurrence (BCR) in patients treated with radical prostatectomy (RP) remains controversial. Methods : We retrospectively evaluated 6842 patients who underwent RP for clinically localized prostate cancer (PC) between 2000 and 2011. Uni- and multivariable cox regression models addressed the association of statin use with BCR. Results : Overall, 2275 (33.3%) patients used statins. Statin users were older and had a higher rate of positive surgical margins than patients not using statins (P-values less than or equal to0.05). Within a median follow-up of 25 months (interquartile range: 8–42 months), 778 (11.4%) patients experienced BCR. Actuarial estimate 5-years BCR-free survival was 82%±1 for patients without statin use and 84±1% for patients using statins (P=0.05); statin use was not associated with BCR (hazard ratio: 0.88, 95% confidence interval: 0.76–1.03, P=0.10) after adjusting for the effects of standard clinicopathologic features. Conclusions : In PC patients undergoing RP, statin use was not independently associated with lower risk of BCR.